In multiple myeloma (MM) and triple-negative breast cancer (TNBC), DYRK2 phosphorylates Rpt3-Thr25 of the 26S proteasome to activate the 26S proteasome, and then promotes the transition of the cell cycle from G1 to S phase29,30. Here, DYRK2 is linked to Miyoshi myopathy.